Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 105.63
LCI's Cash to Debt is ranked higher than
80% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. LCI: 105.63 )
LCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 105.63

Equity to Asset 0.88
LCI's Equity to Asset is ranked higher than
94% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. LCI: 0.88 )
LCI' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.88
Current: 0.88

-0.17
0.88
Interest Coverage 74.73
LCI's Interest Coverage is ranked higher than
65% of the 433 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. LCI: 74.73 )
LCI' s 10-Year Interest Coverage Range
Min: 1.15   Max: 325.48
Current: 74.73

1.15
325.48
F-Score: 7
Z-Score: 22.78
M-Score: -1.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.42
LCI's Operating margin (%) is ranked higher than
79% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. LCI: 12.42 )
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 12.42

-119.46
46.27
Net-margin (%) 8.82
LCI's Net-margin (%) is ranked higher than
77% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. LCI: 8.82 )
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 8.82

-73
28.64
ROE (%) 10.36
LCI's ROE (%) is ranked higher than
82% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. LCI: 10.36 )
LCI' s 10-Year ROE (%) Range
Min: -47.34   Max: 152.33
Current: 10.36

-47.34
152.33
ROA (%) 7.94
LCI's ROA (%) is ranked higher than
86% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. LCI: 7.94 )
LCI' s 10-Year ROA (%) Range
Min: -34.54   Max: 43.07
Current: 7.94

-34.54
43.07
ROC (Joel Greenblatt) (%) 25.80
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. LCI: 25.80 )
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -156.16   Max: 88.68
Current: 25.8

-156.16
88.68
Revenue Growth (%) 1.60
LCI's Revenue Growth (%) is ranked higher than
62% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. LCI: 1.60 )
LCI' s 10-Year Revenue Growth (%) Range
Min: -3.6   Max: 48.4
Current: 1.6

-3.6
48.4
EBITDA Growth (%) 9.80
LCI's EBITDA Growth (%) is ranked higher than
75% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. LCI: 9.80 )
LCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 100
Current: 9.8

0
100
EPS Growth (%) 14.10
LCI's EPS Growth (%) is ranked higher than
78% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. LCI: 14.10 )
LCI' s 10-Year EPS Growth (%) Range
Min: -58.1   Max: 93.5
Current: 14.1

-58.1
93.5
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

LCI Guru Trades in

Q3 2013

LCI Guru Trades in Q3 2013

Steven Cohen 16,217 sh (New)
Jim Simons 198,300 sh (+7.31%)
» More
Q4 2013

LCI Guru Trades in Q4 2013

Paul Tudor Jones 7,818 sh (New)
Jim Simons 188,400 sh (-4.99%)
Steven Cohen 7,348 sh (-54.69%)
» More
Q1 2014

LCI Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 111,800 sh (-40.66%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 36.70
LCI's P/E(ttm) is ranked higher than
75% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. LCI: 36.70 )
LCI' s 10-Year P/E(ttm) Range
Min: 13.82   Max: 185.79
Current: 36.7

13.82
185.79
P/B 4.90
LCI's P/B is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. LCI: 4.90 )
LCI' s 10-Year P/B Range
Min: 0.61   Max: 16.12
Current: 4.9

0.61
16.12
P/S 5.30
LCI's P/S is ranked higher than
62% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. LCI: 5.30 )
LCI' s 10-Year P/S Range
Min: 0.49   Max: 8.76
Current: 5.3

0.49
8.76
PFCF 185.40
LCI's PFCF is ranked higher than
77% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 185.40 )
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 185.4

3.21
342.5
EV-to-EBIT 21.01
LCI's EV-to-EBIT is ranked higher than
82% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. LCI: 21.01 )
LCI' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 687.5
Current: 21.01

6.9
687.5
PEG 14.10
LCI's PEG is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 367.50 vs. LCI: 14.10 )
LCI' s 10-Year PEG Range
Min: 0.2   Max: 77.25
Current: 14.1

0.2
77.25
Shiller P/E 101.00
LCI's Shiller P/E is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 101.00 )
LCI' s 10-Year Shiller P/E Range
Min: 20.78   Max: 358
Current: 101

20.78
358
Current Ratio 6.37
LCI's Current Ratio is ranked higher than
90% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. LCI: 6.37 )
LCI' s 10-Year Current Ratio Range
Min: 0.99   Max: 8.73
Current: 6.37

0.99
8.73
Quick Ratio 5.26
LCI's Quick Ratio is ranked higher than
89% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. LCI: 5.26 )
LCI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 5.26
Current: 5.26

0.26
5.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.40
LCI's Price/Net Cash is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 15.40 )
LCI' s 10-Year Price/Net Cash Range
Min: 14.88   Max: 42.78
Current: 15.4

14.88
42.78
Price/Net Current Asset Value 8.70
LCI's Price/Net Current Asset Value is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 8.70 )
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 3.66   Max: 670
Current: 8.7

3.66
670
Price/Tangible Book 4.90
LCI's Price/Tangible Book is ranked higher than
67% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. LCI: 4.90 )
LCI' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 21.7
Current: 4.9

0.9
21.7
Price/DCF (Projected) 5.40
LCI's Price/DCF (Projected) is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 5.40 )
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 5.6
Current: 5.4

0.57
5.6
Price/Median PS Value 3.30
LCI's Price/Median PS Value is ranked higher than
51% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. LCI: 3.30 )
LCI' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 6.93
Current: 3.3

0.42
6.93
Price/Peter Lynch Fair Value 4.70
LCI's Price/Peter Lynch Fair Value is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. LCI: 4.70 )
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.64   Max: 15.96
Current: 4.7

0.64
15.96
Price/Graham Number 2.80
LCI's Price/Graham Number is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. LCI: 2.80 )
LCI' s 10-Year Price/Graham Number Range
Min: 0.93   Max: 6.23
Current: 2.8

0.93
6.23
Earnings Yield (Greenblatt) 4.70
LCI's Earnings Yield (Greenblatt) is ranked higher than
73% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. LCI: 4.70 )
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 4.7

0.1
14.4
Forward Rate of Return (Yacktman) 8.29
LCI's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. LCI: 8.29 )
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.9   Max: 88.6
Current: 8.29

-2.9
88.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany
Lannett Company, Inc. was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories' Synthroid(r) and Monarch Pharmaceutical's Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations
» More Articles for LCI

Headlines

Articles On GuruFocus.com
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 
comment on LCI Jan 23 2012 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 
Lannett Company Inc Reports Operating Results (10-K) Sep 24 2010 
View on LCI May 17 2010 
Lannett Company Inc Reports Operating Results (10-Q) May 13 2010 

More From Other Websites
INVESTOR ALERT: Investigation of Lannett Company, Inc. Announced by Glancy Binkow & Goldberg LLP Jul 23 2014
Lannett (LCI) Is Today's Dead Cat Bounce Stock Jul 18 2014
Lannett Signs Agreement to Be Exclusive U.S. Distributor of Authorized Generic of Hypertension Drug,... Jul 18 2014
LANNETT CO INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year Jul 17 2014
Lannett Shares Down on Subpoena Receipt from Connecticut AG Jul 17 2014
ATTENTION LANNETT SHAREHOLDERS: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces... Jul 17 2014
Lannett decline on Connecticut probe seems overdone, says Roth Capital Jul 17 2014
Weakness Seen in Lannett Company (LCI): Stock Tumbles 17.1% Jul 17 2014
Lannett Jul 16 2014
SHAREHOLDER ALERT: Investigation on Behalf of Lannett Company, Inc. Investors Announced by Law... Jul 16 2014
Earnings Continue Driving Markets Higher Jul 16 2014
LANNETT CO INC Files SEC form 8-K, Other Events Jul 16 2014
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates Claims on Behalf of Shareholders... Jul 16 2014
07/16/14 Lannett Receives Inquiry From Connecticut Attorney General Jul 16 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lannett Company,... Jul 16 2014
Midday movers: Abbott, Northern Trust, Tesla & More Jul 16 2014
Why Lannett (LCI) Stock Is Down Today Jul 16 2014
Lannett Receives Inquiry from Connecticut Attorney General Jul 16 2014
Lightning Round: Akamai, GE & more Jul 15 2014
Sanchez Energy Among 5 Diverse Top-Rated Companies Jul 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide